Improvement in Itch, Symptoms, and Quality of Life With Upadacitinib Through Week 16 in Adults and Adolescents With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)

被引：0
|
作者：
Lio, Peter [1 ]
Eichenfield, Lawrence F. [2 ,3 ,4 ]
Marcoux, Danielle [5 ]
Lee, Wan-Ju [6 ]
Teixeira, Henrique D. [6 ]
Raymundo, Eliza M. [6 ]
Gamelli, Amy E. [6 ]
Grada, Ayman [6 ]
Hu, Xiaofei [6 ]
Irvine, Alan D. [7 ,8 ]
机构：
[1] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Evanston, IL USA
[2] Univ Calif San Diego, Dept Dermatol, San Diego, CA USA
[3] Univ Calif San Diego, Dept Pediat, San Diego, CA USA
[4] Rady Childrens Hosp San Diego, San Diego, CA USA
[5] Univ Montreal, St Justine Univ Hosp Ctr, Div Dermatol, Dept Pediat, Montreal, PQ, Canada
[6] AbbVie Inc, N Chicago, IL USA
[7] Trinity Coll Dublin, Dept Clin Med, Dublin, Ireland
[8] Dermatol Childrens Hlth Ireland, Dublin, Ireland
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
42065
引用
收藏
页码：AB178 / AB178
页数：1
相关论文
共 50 条
  • [31] Efficacy of upadacitinib for moderate-to-severe atopic dermatitis: analysis of time spent in skin clearance response states from the Measure Up 1, Measure Up 2 and Heads Up studies
    Blauvelt, Andrew
    Silverberg, Jonathan, I
    Calimlim, Brian M.
    Liu, Yingyi
    Platt, Andrew
    Thyssen, Jacob P.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [32] Safety and efficacy of upadacitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis: results from two pivotal, phase III, randomized, double-blinded, monotherapy, placebo-controlled studies (Measure Up 1 and Measure Up 2)
    Guttman-Yassky, E.
    Teixeira, H. D.
    Simpson, E. L.
    Papp, K. A.
    Pangan, A. L.
    Blauvelt, A.
    Thaci, D.
    Chu, C. Y.
    Hong, H. C.
    Katoh, N.
    Paller, A. S.
    Calimlim, B.
    Gu, Y.
    Hu, X.
    Liu, M.
    Yang, Y.
    Tenorio, A. R.
    Chu, A. D.
    Irvine, A. D.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E62 - E62
  • [33] Effect of upadacitinib on SCORAD intensity items: analysis from the Measure Up 1 and Measure Up 2 studies
    Cameron, Michael
    Magnolo, Nina
    Prajapati, Vimal H.
    Haque, Adel
    Lee, Wan-Ju
    Altman, Katherine
    Platt, Andrew M.
    Lane, Michael C.
    Calimlim, Brian M.
    Taieb, Alain
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [34] Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials
    Simpson, Eric L.
    Papp, Kim A.
    Blauvelt, Andrew
    Chu, Chia-Yu
    Hong, H. Chih-Ho
    Katoh, Norito
    Calimlim, Brian M.
    Thyssen, Jacob P.
    Chiou, Albert S.
    Bissonnette, Robert
    Gold, Linda F. Stein
    Wegzyn, Colleen
    Hu, Xiaofei
    Liu, Meng
    Liu, John
    Tenorio, Allan R.
    Chu, Alvina D.
    Guttman-Yassky, Emma
    JAMA DERMATOLOGY, 2022, 158 (04) : 404 - 413
  • [35] Characterization of hematologic and transaminase laboratory findings associated with upadacitinib in moderate-to-severe atopic dermatitis: Results of two phase 3 trials (measure up 1 and 2)
    Silverberg, Jonathan I.
    Gooderham, Melinda J.
    de Bruin-Weller, Marjolein S.
    Papp, Kim A.
    Aoki, Valeria
    Paller, Amy S.
    Ofori, Sarah
    Tenorio, Allan R.
    Liu, Yingyi
    Liu, Jianzhong
    Chovatiya, Raj
    CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (08): : 1010 - 1010
  • [36] Improvement in symptoms of atopic dermatitis (AD) and AD-related quality of life with dupilumab treatment in adults: 24-week results of the DUPISTAD study
    Merola, Joseph
    Chiou, Albert
    During, Emmanuel
    Costanzo, Antonio
    Foley, Peter
    Shumack, Stephen
    Spelman, Lynda
    Rubel, Diana
    Ardeleanu, Marius
    Wu, Jiangming
    Worrell, Richard
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 13 - 14
  • [37] Improvement in symptoms of atopic dermatitis (AD) and AD-related quality of life with dupilumab treatment in adults: 24-week results of the DUPISTAD study
    Merola, Joseph F.
    Chiou, Albert S.
    During, Emmanuel
    Costanzo, Antonio
    Foley, Peter
    Ardeleanu, Marius
    Wu, Jiangming
    Ozturk, Zafer E.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [38] Characterization of haematological and transaminase laboratory findings associated with upadacitinib use in moderate-to-severe atopic dermatitis: results of two phase III Trials (Measure Up 1 and 2)
    Silverberg, J. I.
    Gooderham, M. J.
    de Bruin-Weller, M. S.
    Papp, K. A.
    Aoki, V.
    Paller, A. S.
    Ofori, S.
    Tenorio, A. R.
    Liu, Y.
    Liu, J.
    Chovatiya, Raj
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E168 - E169
  • [39] Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study
    Norito Katoh
    Yukihiro Ohya
    Hiroyuki Murota
    Masanori Ikeda
    Xiaofei Hu
    Kimitoshi Ikeda
    John Liu
    Takuya Sasaki
    Eliza M. Raymundo
    Henrique D. Teixeira
    Hidehisa Saeki
    Dermatology and Therapy, 2023, 13 : 221 - 234
  • [40] Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study
    Katoh, Norito
    Ohya, Yukihiro
    Murota, Hiroyuki
    Ikeda, Masanori
    Hu, Xiaofei
    Ikeda, Kimitoshi
    Liu, John
    Sasaki, Takuya
    Raymundo, Eliza M.
    Teixeira, Henrique D.
    Saeki, Hidehisa
    DERMATOLOGY AND THERAPY, 2023, 13 (01) : 221 - 234
12345